The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Safety and feasibility of rhenium-186 nanoliposome (186RNL) in recurrent glioma: The ReSPECT phase 1 trial.
 
Andrew J. Brenner
Leadership - NanoTX
Stock and Other Ownership Interests - NanoTX; Plus Therapeutics
Honoraria - Vascular Biogenics
Consulting or Advisory Role - Alamab Therapeutics; NanoTX; Plus Therapeutics; Vascular Biogenics
Research Funding - Boston Biomedical (Inst); Immunomedics (Inst); Medicenna (Inst); miRNA Therapeutics (Inst); Threshold Pharmaceuticals; Upsher-Smith (Inst); Vascular Biogenics
Patents, Royalties, Other Intellectual Property - I have intellectual property interest in NanoTx Therapeutics
Travel, Accommodations, Expenses - Vascular Biogenics
 
Ande Bao
Stock and Other Ownership Interests - NanoTX
Consulting or Advisory Role - Plus Therapeutics
Research Funding - Plus Therapeutics
 
William Phillips
Employment - MagForce; NanoTx; Plus Therapeutics
Leadership - NanoTx
Stock and Other Ownership Interests - NanoTx
Consulting or Advisory Role - Plus Therapeutics
Patents, Royalties, Other Intellectual Property - Patent of radio labeled nanoparticle with 99mTc and 186-188 rhenium
 
Gregory Stein
Employment - Curtana; Plus Therapeutics
Leadership - Curtana
Stock and Other Ownership Interests - Curtana; Plus Therapeutics
Consulting or Advisory Role - Plus Therapeutics
Research Funding - Curtana; Plus Therapeutics
Patents, Royalties, Other Intellectual Property - Co-inventor on patent applications related to small molecule Olig2 inhibitors for the treatment of glioblastoma and other cancers.
 
Vibhudutta Awasthi
Employment - Hexakit
Leadership - Hexakit
Stock and Other Ownership Interests - Hexakit
Patents, Royalties, Other Intellectual Property - Received royalty for a University-sponsored patent.
 
Toral R. Patel
Stock and Other Ownership Interests - Abbvie; Edwards Lifesciences; Gilead Sciences; Precigen; Stryker; ZIOPHARM Oncology
Honoraria - Elekta
 
Jeffrey Weinberg
Consulting or Advisory Role - OSTEOMED
 
John Floyd
No Relationships to Disclose